Levofloxacin-13C,d3

• UNSPSC Description:

  Levofloxacin-13C,d3 is the 13C- and deuterium labeled Levofloxacin.

• Target Antigen:

  Antibiotic; Bacterial; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection;Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Purity:

  98.0

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1C2=CC(F)=C(N3CCN(CC3)[13C]([2H])([2H])[2H])C4=C2N(C=C1C(O)=O)[C@@H](C)CO4

• Molecular Weight:

  365.38

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014.|[3]Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014.|[4]Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1261398-33-7